The price of an Indian pharmaceutical stock is in focus as the company’s financial results show a robust Net profit growth of 210 percent YOY and revenue growth of 19% percent. The company has also given capex plans worth more than $20mn US dollars. Read it out
Price action
With a market capitalization of Rs. 34,897 crores on Friday, the shares of Laurus Labs Ltd. were trading at a CMP of Rs 625.85, which is close to 3 percent lower than its previous day’s closing price of Rs 645.50.
What Happened
Laurus Labs Ltd, a fully integrated pharmaceutical and biotechnology manufacturing company, has announced its results for the Financial year ‘25.
Its Revenue grew by 19 percent YoY from Rs. 1440 Crores in Q4FY24 to Rs. 1720 Crores in Q4FY25, and it grew by 21.5 percent QoQ from Rs. 1415 Crores in Q3FY25 to Rs. 1720 Crores in Q4FY25.
Its Net Profit grew by a staggering 210 percent YoY from Rs. 75 Crores in Q4FY24 to Rs. 233 Crores in Q4FY25, and it grew by 150 percent QoQ from Rs. 92.9 Crores in Q3FY25 to Rs. 233 Crores in Q4FY25
The company’s EBIDT has also grown by 74 percent YOY from Rs. 241 crores in Q4FY24 to Rs. 421 crores in Q4FY25, and it has increased by 47 percent QoQ from Rs. 285 crores in Q3FY25 to Rs. 421 crores in Q4FY25.The EPS of the company has grown by 209 percent from Rs. 1.40 in Q4FY24 to Rs. 4.33 in Q4FY25
Capex plans
The company has also announced a capex plan worth more than 20 million USD for committing to build a GMP Facility in Hyderabad, which is to be completed by March
2026
About the company
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C, and Oncology. Laurus Labs has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients.
Written by Likesh Babu S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
